Table 4 In vitro inhibitory effect (expressed as IC50) of the most potent combinations of antibiotic anti-septic regimens against PAF-induced WRPs aggregation
|  |  | IC502towards PAF in WRPs (μg/mL) |  |  | ||
|---|---|---|---|---|---|---|
Combinations of Bioactive Compounds | Ratio1 | Median | Min | Max | Geometric Mean | 95% Confidence Interval |
Piperacillin-Tazobactam/Netilmicin | 40-5/1 | 5.1-0.6/0.1 | 4.6-0.6/0.1 | 5.3-0.7/0.1 | 5.0-0.6/0.1 | 4.2 thru 6.0-0.5 thru 0.8/0.1 thru 0.1 |
Piperacillin-Tazobactam/Amikacin | 40-5/1.7 | 5.1-0.6/0.2 | 4.6-0.6/0.2 | 5.4-0.7/0.2 | 5.1-0.6/0.2 | 4.2 thru 6.1-0.5 thru 0.8/0.2 thru 0.2 |
Ceftazidime/Amikacin | 6/1 | 10.0/1.7 | 7.4/1.2 | 13.1/2.6 | 9.9/1.7 | 4.9 thru 20.1/0.7 thru 4.6 |
Ceftazidime/Netilmicin | 10/1 | 10.6/1.1 | 7.8/0.8 | 14.3/1.4 | 10.6/1.1 | 5.0 thru 22.5/0.5 thru 2.2 |
Meropenem/Netilmicin | 10/1 | 15.3/1.5 | 12.2/1.2 | 21.4/2.1 | 15.9/1.6 | 7.9 thru 32.0/0.8 thru 3.1 |
Meropenem/Amikacin | 6/1 | 22.5/3.8 | 18.8/3.1 | 31.9/5.3 | 23.8/4.0 | 12.2 thru 46.4/2.0 thru 7.8 |